APPLIED BIOSYSTEMS/MILLIPORE FUND UNIV. OF TOKYO PROTEOMICS.

Applied Biosystems Japan, Ltd., a unit of Applied Biosystems Group (NYSE: ABI), an Applera Corporation business, and Nihon Millipore KK, a unit of Millipore Corporation (NYSE: MIL) have jointly opened the Donation Department of Proteomics Research at the Institute of Medical Science at the University of Tokyo (IMSUT), with the support of IMSUT, represented by Dr. Kenichi Arai, Dean of IMSUT.

The Donation Department of Proteomics Research is a three-year project focused on developing new techniques for protein expression profiling and for the analysis of protein-to-protein interactions at the cellular level. The center was formed with the assistance of Dr. Kenichi Arai, Dean of IMSUT. Dr. Toshiaki Isobe, Visiting Professor of the University of Tokyo (at present, Professor at Tokyo Metropolitan University) will direct the new department. Dr. Isobe will facilitate cooperative projects in different research areas such as the expression and functional analysis of proteins, which require the development and fusion of various technologies from different research disciplines.

"The Donation Department of Proteomics Research represents a collaboration between academia and industry. The goal will be the creation of a technical platform for genome-based drug discovery," Dr. Arai said.

"By leveraging the combined expertise of all three collaborators, the formation of the Donation Department of Proteomics Research may lead to new technologies that could play a pivotal role in the acceleration of protein research," said Dr. Michael W. Hunkapiller, President of Applied Biosystems.

Fran Lunger, CEO and President of Millipore, said, "We're very pleased to be working with the University of Tokyo and our partner Applied Biosystems on this project. Life sciences research is a priority worldwide, and these relationships are effective in accelerating that important work."

About Applera Corporation and Applied Biosystems

Applera Corporation comprises two operating groups. The Applied Biosystems Group develops and markets instrument-based systems, reagents, software, and contract services to the life science industry and research community. Customers use these tools to analyze nucleic acids (DNA and RNA), small molecules, and proteins to make scientific discoveries, leading to the development of new pharmaceuticals, and to conduct standardized testing. Applied Biosystems is headquartered in Foster City, CA, and reported sales of $1.6 billion during fiscal 2001.

The Celera Genomics Group, an integrated sourceof genomic and related medical information headquartered in Rockville, MD, is evolving to become a next generation therapeutic discovery business. Celera intends to leverage its industrialized approach to biology to develop platforms for enabling these new discoveries both for its own internal product development and for its customers, including collaboration partners and subscribers. Celera Diagnostics has been established as a joint venture between Applied Biosystems and Celera Genomics. This new venture is focused on discovery, development and commercialization of novel diagnostic tests.

For more information, visit http://www.appliedbiosystems.com and visit http://www.applera.com, or call 800.762.6923 or 650/554-2550.

About Millipore

Millipore is a multinational, high technology company that provides technologies, tools and services for the development and production of new therapeutic drugs. It serves the life science research, biotechnology and pharmaceutical industries.

For more information, visit www.millipore.com or call 781/533-2225 or 800/225-3384.